Skip to main content
Fig. 2 | Lipids in Health and Disease

Fig. 2

From: Polar lipids modify Alzheimer’s Disease pathology by reducing astrocyte pro-inflammatory signaling through platelet-activating factor receptor (PTAFR) modulation

Fig. 2

A DI TNC1 cells were treated with 1 µM Aβ peptide or 1 µg/µl LPS for 24 h and compared to untreated controls. qRT-PCR using rat ptafr specific primers and hmbs as housekeeping gene for normalization reveals a significant increase in ptafr gene expression after activation of astrocytes by LPS and Aβ (one-way ANOVA, p<0.0001; Tukey posthoc test: Ctrl vs. LPS p<0.001; Ctrl vs. Aβ p=0.0235; Aβ vs. LPS p<0.001, n=3-4). B, C Immunocytochemistry confirms the increase in protein level. 24 h after treatment with 1 µM Aβ peptide, PTAFR fluorescent signals are significantly increased (t-test, p=0.0008, n=15). (AFU: Absolute Fluorescence Units). C Exemplary images of PTAFR fluorescence after treatment. Scale bar = 30 μm. D Western blotting further confirms an increase of PTAFR on protein level after exposure to LPS and Aβ (one-way ANOVA, p<0.0001; Tukey posthoc test: Ctrl vs. LPS p=0.0145; Ctrl vs. Aβ p=0.0100; Aβ vs. LPS p=0.00100, n=3). Tubulin was used as a housekeeping protein for normalization. The exposure time was reduced for the Aβ condition to avoid overexposure of the PTAFR band

Back to article page